Kynamro is an orphan drug approval, meaning it was developed to treat a disorder affecting fewer than 200,000 people in the whole world ans ISIS have to compete with Juxtapid (lomitapide) it is very small market no revenue I would not surprise if the stock go negative tomorrow.
I am not sure why it would go negative tomorrow.We have already been at 14.40 before the pull back last week. KERX the last 2 days has gone from 3.50-8, just because it made stage 4 testing.
So why would we not go higher tomorrow??? After a run up then I expect some kind of a profit taking pull back, but not tomorrow.
Anyone else agree??
Ironically, I think the newer products about to hit are even more underscored by today's events. I think it will dip, then flatten and until a REAL ANALYST gives REAL REASONS TO BUY, not guessing, then institutions have the run of it. If Institutions had a brain, this would be off the public market already. They are mostly lucky or cheat insider traders so I would not expect many to recognize what this approval means. EMA looks like grotesque freaks about now.